mRNA Victoria’s Post

Presenting React4life's MIVO® Platform, a groundbreaking invention in #organ on a chip #technology, designed to revolutionize #biomedical research. MIVO® replicates human tissue complexity and simulates systemic drug interactions, providing an advanced, high-throughput system for #DrugScreening and #DiseaseModeling. By leveraging human-relevant models, MIVO® empowers #PharmaceuticalCompanies, #ResearchCenters and #hospitals to accelerate drug discovery, reduce development costs, and improve therapeutic outcomes. This innovative platform bridges the gap between preclinical testing and clinical results, offering insight into how drugs interact within the human body. With React4life, you're equipped to explore new frontiers in #PersonalizedMedicine, delivering faster, more accurate solutions for patients worldwide. Learn how MIVO® is transforming the future of biomedical research at www.react4life.com or connect with Silvia Scaglione. #BiomedicalInnovation #PharmaTech #ResearchExcellence #DrugDiscovery #PrecisionMedicine

Excited to kick off 2025 with a strong presence at key healthcare conferences in the U.S.! Join me and our Chairman, Mark Germain, as we connect with industry leaders to drive innovation in immunotherapeutics and biologics. Looking forward to collaborating with investors, pharma partners, and prospective clients. Let's make this year impactful! #VHH #MaxPlanck #Immunotherapy #Biologics #CDMO #Biotech #InvestmentOpportunities #HealthcareConferences #antibodies #Immunology #inflammation #psoriasis

🌟 Only 15 Days Left Until the Sino Biological Symposium on Immuno-Oncology! 🌟 We're thrilled to invite you to the Sino Biological Symposium, a pivotal gathering that highlights monumental advancements in the realm of Immuno-oncology. This event will focus on cutting-edge antibody engineering and the transformative journey of drug discovery from inception to commercialization. 🔬Why Attend?🔬 Engage with a distinguished panel of industry leaders from #Anaveon_AG, #Curio_Biotech, #University_of_Basel, #GIO_Therapeutics, and #Sino_Biological Dive deep into discussions about the role of innovative technology in enhancing drug development processes, accelerating scientific breakthroughs, and ensuring therapeutic safety. Foster rich dialogue, exchange knowledge, and catalyze partnerships that push the boundaries of healthcare innovation. 🌐 Event Details: #Date: Thursday, 16th of May 2024 #Venue: Novartis Pavillon, Basel, Switzerland #Organized by: Sino Biological Europe GmbH 👥 Who Should Attend?👥 If you're a professional in the biotech, pharmaceutical, healthcare, or academic sectors, or simply interested in the future of healthcare innovations, this symposium is for you! Secure your spot now and be part of shaping the future of Immuno-oncology. Let’s pave the way for new collaborations and advancements within the life sciences sector. 🔗🔗🔗 Click here to register and learn more: https://lnkd.in/eZVTKpcK We can't wait to see you there! #SinoBiological #ImmunoOncology #DrugDiscovery #AntibodyEngineering #HealthcareInnovation #BiotechEvent #PharmaIndustry #LifeSciences

Reflecting on PODD conference, here are my three key takeaways: 1.   As Kurt Sedo of Pharmacircle noted in his hugely enjoyable, breathless review of the pharma R&D world over the past year, injectables continue to race ahead of other routes of administration, and last year overtook oral dose forms in terms of new molecules. And this isn’t all GLP-1! 2.   While the clinical diagnostics industry has had a difficult time since the investment boom triggered by the pandemic, it seems that the acceleration in mRNA and lipid nanoparticle (LNP) technology brought about by the warp speed approvals of vaccines has triggered a huge number of biotech developments. Some fascinating presentations on curative therapies, CRISPR and ex-liver delivery to name just a few topics. 3.   As ever, the payer perspective delivered a bit of a reality check. One of the speakers noted that science has significantly outpaced the ability of healthcare systems to pay for its innovations in recent years. All the more important then to think about new therapies as products, and ensure that realistic appraisals of the requirements for market access are built into R&D processes, TPPs etc. Finally, it was genuinely great to reconnect with friends and clients, and to spend time working with my excellent new colleague Matt Jones, who was also at the conference. His takeaways here: https://lnkd.in/egNR-jQe

Looking to increase the durability, tolerability and targeted deliverability of your mRNA payloads across indications and modalities? ... look no further than the 4th mRNA-Based Therapeutics Summit, bringing 400+ mRNA experts and enthusiasts to Boston this July 29-31. See the full program and session details: https://ter.li/1w94zh Here's an overview of what to expect: ⭐ 4 tracks of content spanning Discovery, Translation, Clinical Development, and Chemistry, Manufacturing & Controls ⭐ 2 pre-conference focus days spanning Regulatory Affairs Strategy and Next Generation mRNA Delivery ⭐ 65+ world-class speakers from the likes of the FDA, EMA, CureVac, Replicate Biosciences, Orbital Therapeutics, Sail Biomedicines and more This is a unique opportunity to gain oversight of the entire mRNA value chain, brushing shoulders with CXOs, scientists, regulatory bodies, large pharma, small biotechs, leading academics, expert service and solution providers, and much more. Download the agenda to learn more: https://ter.li/1w94zh #mRNA #mRNASummit #RNA #mRNAVaccines #mRNATherapeutics #WorldRNA

Today's #biotechnews gives us a peek at what's coming next in medicine. Roche just spent a lot of money scooping up two smaller companies with promising new drugs. One deal could lead to better options for #breastcancerpatients when current meds stop working, while the other could help improve eye treatments for people with vision problems. Targeting specific health issues like this can often help lead to breakthroughs for #biotech companies—and potential investment opportunities for the rest of us! https://loom.ly/jQc4NcY

Tackling questions and challenges of mRNA therapeutics productions? We got you 💪 This webinar series covers raw material selection, the benefits of a magnetic bead-based approach, and mRNA identity testing methods with insights from discovery to commercial manufacturing. Don't miss this opportunity to deepen your knowledge in this rapidly evolving field. Watch on-demand now ⏯️ https://lnkd.in/gkF_SisB #mRNA #NucleicAcidTherapeutics #Biotechnology #Webinar #iLoveMolBio

Tackling questions and challenges of mRNA therapeutics productions? We got you 💪 This webinar series covers raw material selection, the benefits of a magnetic bead-based approach, and mRNA identity testing methods with insights from discovery to commercial manufacturing. Don't miss this opportunity to deepen your knowledge in this rapidly evolving field. Watch on-demand now ⏯️ https://lnkd.in/gkF_SisB #mRNA #NucleicAcidTherapeutics #Biotechnology #Webinar #iLoveMolBio

🔬 A Breakthrough for the Future of Medicine: Philadelphia Business Journal John George went onsite to ThirdLaw Molecular's labs and dives into the science for the new magical molecules. What does this mean for patients? Temple University spinout ThirdLaw Molecular's 'lock and key' molecule looks to make drug creation faster and less expensive Article here: https://lnkd.in/eage7TUK Imagine a world where drug treatments are faster, more precise, and more affordable—where diseases once considered untreatable finally have solutions. ThirdLaw Molecular, led by Christian Schafmeister is making that future a reality with its groundbreaking Spiroligomer™ macromolecules. For patients, this innovation could mean: ✅ New hope for “undruggable” diseases – Spiroligomers can target proteins that small molecules and biologics cannot. ✅ Faster drug development – Bringing life-changing treatments to market quicker. ✅ More effective, personalized therapies – Reducing side effects and improving outcomes. ✅ Greater accessibility – A shift toward more scalable, cost-effective drug manufacturing. With $16M in DoD grants and a newly launched 4.5 billion-molecule DNA-encoded library, ThirdLaw is leading the charge toward a future where medicine is smarter, safer, and more tailored to each patient’s needs. This is more than just a scientific breakthrough—it’s a transformational moment for healthcare. 📖 Learn more: https://lnkd.in/exsrJbWR #FutureOfMedicine #PrecisionMedicine #DrugDiscovery #PatientImpact #ThirdLawMolecular #Spiroligomer #HealthcareInnovation

Great feature by the @philadelphia business journal on the incredible work by the ThirdLaw Molecular team, led by Dr. Christian Schafmeister. The company is pioneering Spiroligomer™ macromolecules—a breakthrough technology that has the potential to revolutionize drug discovery! 🚀 With the recent launch of a 4.5 billion-molecule DNA-encoded library, ThirdLaw is opening new doors for precision medicine, making drug development faster, more targeted, and cost-effective. This is a huge step forward for tackling previously undruggable disease targets! 🔬 Backed by $16M in DoD grants and a $1.5M seed round, this team is on an exciting trajectory to reshape the future of biotech and pharma innovation. Congratulations to the entire ThirdLaw Molecular team—your dedication and innovation are truly inspiring! Looking forward to seeing what’s next.